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Abstract
Metastatic disease to the orbit occurs in up to 7% of cancers. In approximately 20% of cases, there
is no diagnosis of cancer at the time of presentation with orbital metastatic disease. This is a case
of a 53-year-old female smoker whose initial presentation of metastatic non-small cell lung cancer
was with an orbital metastasis.
Case presentation
A 53-year-old Caucasian woman presented with a one
month history of a painful right eye associated with
decreased vision and diplopia. Her only other symptom
was right knee pain. Past medical history was unremarka-
ble and she took no medications. She had smoked 20 cig-
arettes per day for approximately 35 years. She drank
alcohol only occasionally. She worked as a receptionist,
and had no children. There was no family history of
malignancy.
On examination, she was a well-looking woman. Height
was 165 cm and weight 60 kg. Vital signs were within nor-
mal limits. Examination of the right eye revealed conjunc-
tival injection, proptosis, markedly reduced visual acuity,
and restricted extra-ocular movements (particularly lateral
gaze). The rest of the physical examination was unremark-
able, apart from mild tenderness over the distal right
femur.
Computed tomography (CT) of the brain demonstrated
an enhancing 2.1 × 1.6 cm right orbital mass. Histology
from a fine needle aspiration biopsy (FNAB) was consist-
ent with a moderately differentiated, mucin-producing
adenocarcinoma. On immunohistochemistry, cytokeratin
7 (CK7) was positive; however cytokeratin 20 (CK20), car-
cinoembryonic antigen (CEA), estrogen and progesterone
receptors were all negative. Interestingly, thyroid tran-
scription factor-1 was also negative, which is unusual for
primary lung adenocarcinoma [1].
After referral to medical oncology, further investigations
were performed. Tumour markers (CEA, CA-125, CA
15.3) were normal. CT of the chest and abdomen revealed
a spiculated 1.7 cm lesion in the left lower lobe and a 2.3
cm left adrenal mass. Whole body bone scan showed
widespread osteoblastic bone metastases, including the
distal right femur. Magnetic resonance imaging (MRI) of
the brain demonstrated the right orbital mass which was
abutting the right lateral rectus muscle and displacing the
optic nerve (see Figure 1).
Despite TTF-1 being negative, the diagnosis of metastatic
adenocarcinoma of the lung was made due to the history
of smoking and radiological pattern of disease. Given the
burden of systemic disease, the patient was commenced
on chemotherapy with a view to administering radiother-
apy to the right eye at a later date. Carboplatin (area under
the curve 5; day 1) and vinorelbine (25 mg/m2, day 1 and
day 8) were given in 3 weekly cycles. At the time of writ-
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ing, the patient had received three cycles of treatment. She
had stable disease on restaging and no significant toxicity.
Metastatic disease to the eye most commonly involves the
choroid [2]. By comparison, metastatic disease to the orbit
is relatively uncommon, occurring in up to 7% of all can-
cers [3]. Metastases to the orbit also account for less than
5% of all orbital tumours [4]. The commonest primary
tumour sites for orbital metastases include breast, prostate
and lung [5]. In approximately 20% of cases, orbital
metastases are the initial manifestation of systemic malig-
nancy [6]; this is more common with lung rather than
breast cancers [7].
Compared with CT, MRI provides superior resolution of
both orbital and intracerebral metastases, which are not
uncommon in the setting of an orbital metastasis [8]. The
diagnosis can be confirmed with FNAB or at the time of
excision. FNAB is diagnostic in greater than 90% of cases
[9].
Local control is achieved with surgery or radiotherapy;
however in the setting of significant systemic disease, local
control may need to be deferred to allow administration
of systemic treatment. The typical dose of radiotherapy is
30–50 Gy, with up to 90% of patients experiencing symp-
tomatic improvement [10]. However, most patients also
require systemic treatment. The prognosis of patients with
metastatic disease to the orbit is poor. Median survival is
typically just over one year, although breast carcinoma
patients have slightly better outcomes [6,7].
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Coronal T1 MRI brain and orbit Figure 1
Coronal T1 MRI brain and orbit. MRI performed 2 
weeks after fine needle aspiration biopsy of the right orbital 
mass, but prior to commencing chemotherapy. The right 
orbital mass is shown causing displacement of the optic 
nerve.